Malignant gliomas may be treated with surgery, radiation, chemotherapy, or any combination of these treatment options. The treatment your doctor recommends depends on various factors including the type of tumor, its location, and its size.

  • Involves removal of the entire tumor. If this is not possible, the surgeon will remove as much of the tumor as possible without damaging surrounding healthy tissue. Sometimes surgery may improve symptoms.
  • GLIADEL® Wafer
  • Considered an intraoperative chemotherapy treatment. For patients who meet the appropriate criteria, up to 8 wafers can be implanted into the surgical cavity during surgery following removal of the tumor. It can only be given during this time.
  • Medical use of high energy radiation to kill malignant brain tumor cells. The purpose is to target the tumor and avoid the surrounding tissue as much as possible. It is normally administered in low doses. Involved field radiotherapy is a more precise form of radiotherapy that specifically treats the affected area of the brain. Stereotactic radiosurgery delivers a single high dose of radiation directly to the targeted tumor.
  • Consists of medicines given to kill cancer cells. Chemotherapy can be given orally, through an intravenous injection directly into the bloodstream, or implanted into the surgical cavity following removal of the tumor.

Your treatment will most likely involve a team of specialists including neurosurgeons, neuro-oncologists, medical oncologists, radiologists/radiation oncologists, neurologists, and nurses. Your treatment team may prescribe other medications to help you cope with the symptoms of your tumor or the side effects of your treatment.



GLIADEL Wafer (carmustine implant) is indicated in patients with newly diagnosed high-grade malignant glioma as an adjunct to surgery and radiation.

GLIADEL Wafer is also indicated in patients with recurrent glioblastoma multiforme as an adjunct to surgery.


You should not be given GLIADEL Wafer if you are allergic to carmustine or any of the components of GLIADEL Wafer.

If you are undergoing surgery for malignant glioma and implantation of GLIADEL Wafer, you should be monitored closely for known complications, including convulsions, infections, abnormal wound healing, and swelling of the brain.

If you are pregnant or are planning to become pregnant, you should understand that carmustine, the active component of GLIADEL Wafer, can cause harm to the fetus if given to a pregnant woman. It is not known if either carmustine, or other components of GLIADEL Wafer are excreted in human milk. Many drugs are excreted in human milk and there is a risk for serious side effects from carmustine in nursing infants; therefore discontinuation of nursing is recommended if you will be receiving GLIADEL Wafer.

It is possible that if GLIADEL Wafers are not implanted properly, they could block the flow of cerebrospinal fluid and might cause abnormal accumulation of fluid in the brain (obstructive hydrocephalus).

The short-term and long-term safety of GLIADEL Wafer when given together with chemotherapy is not fully known.

Following surgery to remove a brain tumor and implantation of GLIADEL Wafer, the following side effects have been reported in clinical studies:

Seizures (convulsions): In clinical studies, seizures have occurred within days or several weeks following implantation of GLIADEL Wafer. Both new seizures and worsening of seizures have been reported.

Brain Swelling: Brain swelling has occurred in clinical studies. In some cases, brain swelling may require another surgery, and removal of GLIADEL Wafers or remnants of the wafers may be required.

Abnormal wound healing: In clinical studies, abnormal healing of the surgical wound has occurred following implantation of GLIADEL Wafer. These abnormalities included reopening of the surgical area, leaking of brain or spinal fluid, delays in healing, or other abnormalities in how the wound heals.

Brain Infections: In clinical studies, brain infections, including meningitis, have occurred following implantation of GLIADEL Wafer.


The most common adverse reactions in Newly-Diagnosed High Grade Malignant Glioma patients are cerebral edema, asthenia, nausea, vomiting, constipation, wound healing abnormalities and depression. The most common adverse reactions in Recurrent Glioblastoma Multiforme patients are urinary tract infection, wound healing abnormalities and fever.

Please read the full Prescribing Information and discuss it with your doctor or healthcare professional. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit or call 1-800-FDA-1088.